Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Laekna, Inc. ( (HK:2105) ) is now available.
Laekna, Inc. reported positive topline data from a U.S. Phase I single ascending dose study of its monoclonal antibody LAE102 in healthy postmenopausal women, showing a well-tolerated safety profile with no serious adverse events. The trial demonstrated dose-dependent improvements in body composition, with the highest exposure group achieving a notable increase in lean mass and a slight reduction in fat mass versus placebo, alongside strong and sustained target engagement.
These findings reinforce LAE102’s potential as a novel precision therapy for cardiometabolic diseases and quality weight control, particularly as an add-on to incretin-based treatments in patients with higher BMI and related comorbidities. Laekna is preparing Phase 2 trials and is in active discussions with potential partners to accelerate global development and commercialization of LAE102, which could enhance its competitive position in the rapidly expanding obesity and metabolic disease treatment market.
The most recent analyst rating on (HK:2105) stock is a Buy with a HK$24.16 price target. To see the full list of analyst forecasts on Laekna, Inc. stock, see the HK:2105 Stock Forecast page.
More about Laekna, Inc.
Laekna, Inc. is a biopharmaceutical company focused on developing precision therapies for cardiometabolic diseases and weight management. Its pipeline includes LAE102, an internally discovered monoclonal antibody targeting the ActRIIA receptor, aimed at improving body composition in overweight and obese patients, including those treated with GLP-1 receptor agonists.
Average Trading Volume: 2,099,417
Technical Sentiment Signal: Sell
Current Market Cap: HK$5.46B
See more insights into 2105 stock on TipRanks’ Stock Analysis page.